Elite Pharmaceuticals, Inc.Private▼ Negative
Capitalrelevance
Stock fell 13.7% despite record earnings, indicating market disappointment or profit-taking.
Elite Pharmaceuticals shares have dropped 13.7% since reporting record results for the fiscal year ended March 31, 2026, underperforming the S&P 500's 1.8% gain. Total revenues surged 77.1% to $148.9 million, operating income jumped 150.6% to $49.1 million, and net income reached $44.9 million compared with a net loss of $4.3 million a year earlier. Manufacturing fee revenues rose 80.3% to $147.8 million, while licensing fees fell 48.5% to $1.1 million as the company shifted toward sales under its own Elite label. Gross profit increased 87.2% to $75 million, with gross margin expanding to 50% from 48%, driven by a more favorable product mix. Management highlighted full-year contributions from Lisdexamfetamine capsules, the launch of Oxycodone/Acetaminophen tablets, and the transition of Naltrexone and Phentermine to exclusive Elite-label sales as key growth drivers, while noting that future expansion will depend on pipeline development and pending ANDA filings.
Stock fell 13.7% despite record earnings, indicating market disappointment or profit-taking.